Request for Input To Inform a Possible Surgeon General Action on Prescription Drug Abuse in Youth, 24901 [2011-10735]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 85 / Tuesday, May 3, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Request for Input To Inform a Possible
Surgeon General Action on
Prescription Drug Abuse in Youth
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
srobinson on DSKHWCL6B1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
Name of Committee: National Institute on
Aging Initial Review Group, Behavior and
Social Science of Aging Review Committee.
Date: June 1–2, 2011.
Time: 4 p.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Guest Suites Santa
Monica, 1707 Fourth Street, Santa Monica,
CA 90401.
Contact Person: Jeannette L. Johnson, PhD,
Scientific Review Officer, National Institute
on Aging, National Institutes of Health, 7201
Wisconsin Avenue, Suite 2c–212, Bethesda,
MD 20892, 301–402–7705,
johnsonj9@nia.nih.gov.
Name of Committee: National Institute on
Aging Initial Review Group, Clinical Aging
Review Committee.
Date: June 2–3, 2011.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Guest Suites Santa
Monica, 1707 Fourth Street, Santa Monica,
CA 90401.
Contact Person: Alicja L. Markowska, PhD,
DSC, National Institute on Aging, National
Institutes of Health, Gateway Building 2c212,
7201 Wisconsin Avenue, Bethesda, MD
20892, 301–496–9666,
markowsa@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: April 25, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–10668 Filed 5–2–11; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
20:39 May 02, 2011
Jkt 223001
National Institute on Drug
Abuse, National Institutes of Health,
Department of Health and Human
Services (HHS).
ACTION: Request for information.
The National Institute on
Drug Abuse, a Research Institute of the
National Institutes of Health, is seeking
on behalf of the Department of Health
and Human Services information for an
anticipated Surgeon General response to
the public health problem of
prescription drug abuse among youth.
SUPPLEMENTARY INFORMATION:
Scope of Problem: Prescription drug
abuse 1 remains a looming public health
threat in this country. Unlike illicit drug
use, which has shown a continuing
downward trend, prescription drug
abuse, particularly of opioid pain
medications, has seen a continual rise
through the 1990s and has remained
stubbornly steady among persons 12 or
older during recent years. Most abusers
are between the ages of 18 and 25, but
younger age groups are also a major
concern.
Approach: ONDCP highlighted
prescription drug abuse in its 2010
National Drug Control Strategy. At that
time, ONDCP outlined a plan of action
to address the prescription drug abuse
problem, which included engaging the
Office of the Surgeon General to help
bring it needed attention. A multiagency federal work group was formed
to follow through on facilitating a
Surgeon General response. To date, the
work group has received expert input on
the state of the science for addressing
prescription drug abuse among youth,
including from scientific researchers,
public health officials, clinicians, and
military and law enforcement
personnel. Expectations are that a
review of the information collected will
lead to the issuance of a Surgeon
General publication.
Potential Areas of Focus: Extent of the
problem and its consequences;
differences in prescription drug abuse
motivations and how they might inform
SUMMARY:
1 Prescription drug abuse is defined here as the
intentional use of a medication without a
prescription; in a way other than as prescribed; or
for the experience or feeling elicited. It is used
interchangeably with ‘‘nonmedical’’ use, a term
employed by many of the National Surveys. This
definition does not include use for self-harm
(suicide attempts).
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
24901
prevention approaches; availability and
adaptability of evidence-based
prevention programs; the design of
media messages for a wide range of
stakeholders; and possible roles for
health care professionals, parents,
community stakeholders, law
enforcement, policymakers, and others
addressing this problem.
Purpose of Notice: The purpose of this
notice is to provide individuals and
organizations the opportunity to
identify issues and areas of need for
consideration as we gather information
for an anticipated Surgeon General
response to the public health problem of
prescription drug abuse among youth.
Comments must be in writing and
should not exceed 500 words. All
comments will receive careful
consideration. However, persons and
organizations submitting comments will
not receive individual responses.
DATES: Individuals and organizations
interested in providing information
must submit their comments on/or
before June 2, 2011. Comments received
after this date will not be considered.
ADDRESSES: Comments may be
submitted by any one of the following
methods:
• Mail: Anna Staton, M.P.A., Office of
Science Policy and Communications,
National Institute on Drug Abuse, 6001
Executive Boulevard, Suite 5230, MSC
9591, Bethesda, MD 20892–9591; or
• E-mail: Send to
comments4sg@nih.gov.
FOR FURTHER INFORMATION CONTACT:
Mary Beth Bigley, Dr.P.H., M.S.N.,
A.N.P., Acting Director, Office of
Science and Communications, Office of
the Surgeon General, by telephone at
202–205–5642, or e-mail at
Marybeth.Bigley@hhs.gov.
Dated: April 27, 2011.
Mary Affeldt,
Executive Officer, NIDA, National Institutes
of Health.
[FR Doc. 2011–10735 Filed 5–2–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Office of the Secretary
[Docket No. DHS–2011–0019]
Privacy Act of 1974; Department of
Homeland Security United States
Coast Guard—DHS/USCG–002
Employee Assistance Program
Records System of Records
AGENCY:
E:\FR\FM\03MYN1.SGM
Privacy Office, DHS.
03MYN1
]]>Agencies
[Federal Register Volume 76, Number 85 (Tuesday, May 3, 2011)]
[Notices]
[Page 24901]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-10735]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Input To Inform a Possible Surgeon General Action on
Prescription Drug Abuse in Youth
AGENCY: National Institute on Drug Abuse, National Institutes of
Health, Department of Health and Human Services (HHS).
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: The National Institute on Drug Abuse, a Research Institute of
the National Institutes of Health, is seeking on behalf of the
Department of Health and Human Services information for an anticipated
Surgeon General response to the public health problem of prescription
drug abuse among youth.
SUPPLEMENTARY INFORMATION:
Scope of Problem: Prescription drug abuse \1\ remains a looming
public health threat in this country. Unlike illicit drug use, which
has shown a continuing downward trend, prescription drug abuse,
particularly of opioid pain medications, has seen a continual rise
through the 1990s and has remained stubbornly steady among persons 12
or older during recent years. Most abusers are between the ages of 18
and 25, but younger age groups are also a major concern.
---------------------------------------------------------------------------
\1\ Prescription drug abuse is defined here as the intentional
use of a medication without a prescription; in a way other than as
prescribed; or for the experience or feeling elicited. It is used
interchangeably with ``nonmedical'' use, a term employed by many of
the National Surveys. This definition does not include use for self-
harm (suicide attempts).
---------------------------------------------------------------------------
Approach: ONDCP highlighted prescription drug abuse in its 2010
National Drug Control Strategy. At that time, ONDCP outlined a plan of
action to address the prescription drug abuse problem, which included
engaging the Office of the Surgeon General to help bring it needed
attention. A multi-agency federal work group was formed to follow
through on facilitating a Surgeon General response. To date, the work
group has received expert input on the state of the science for
addressing prescription drug abuse among youth, including from
scientific researchers, public health officials, clinicians, and
military and law enforcement personnel. Expectations are that a review
of the information collected will lead to the issuance of a Surgeon
General publication.
Potential Areas of Focus: Extent of the problem and its
consequences; differences in prescription drug abuse motivations and
how they might inform prevention approaches; availability and
adaptability of evidence-based prevention programs; the design of media
messages for a wide range of stakeholders; and possible roles for
health care professionals, parents, community stakeholders, law
enforcement, policymakers, and others addressing this problem.
Purpose of Notice: The purpose of this notice is to provide
individuals and organizations the opportunity to identify issues and
areas of need for consideration as we gather information for an
anticipated Surgeon General response to the public health problem of
prescription drug abuse among youth. Comments must be in writing and
should not exceed 500 words. All comments will receive careful
consideration. However, persons and organizations submitting comments
will not receive individual responses.
DATES: Individuals and organizations interested in providing
information must submit their comments on/or before June 2, 2011.
Comments received after this date will not be considered.
ADDRESSES: Comments may be submitted by any one of the following
methods:
Mail: Anna Staton, M.P.A., Office of Science Policy and
Communications, National Institute on Drug Abuse, 6001 Executive
Boulevard, Suite 5230, MSC 9591, Bethesda, MD 20892-9591; or
E-mail: Send to comments4sg@nih.gov.
FOR FURTHER INFORMATION CONTACT: Mary Beth Bigley, Dr.P.H., M.S.N.,
A.N.P., Acting Director, Office of Science and Communications, Office
of the Surgeon General, by telephone at 202-205-5642, or e-mail at
Marybeth.Bigley@hhs.gov.
Dated: April 27, 2011.
Mary Affeldt,
Executive Officer, NIDA, National Institutes of Health.
[FR Doc. 2011-10735 Filed 5-2-11; 8:45 am]
BILLING CODE 4140-01-P
